Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, 420 Delaware St SE, MMC 609, Minneapolis, MN 55455, USA.
Molecules. 2021 May 3;26(9):2674. doi: 10.3390/molecules26092674.
Ovarian cancer is the most lethal gynecologic malignancy among women. Approximately 70-80% of patients with advanced ovarian cancer experience relapse within five years and develop platinum-resistance. The short life expectancy of patients with platinum-resistant or platinum-refractory disease underscores the need to develop new and more effective treatment strategies. Early detection is a critical step in mitigating the risk of disease progression from early to an advanced stage disease, and protein biomarkers have an integral role in this process. The best biological diagnostic tool for ovarian cancer will likely be a combination of biomarkers. Targeted proteomics methods, including mass spectrometry-based approaches, have emerged as robust methods that can address the chasm between initial biomarker discovery and the successful verification and validation of these biomarkers enabling their clinical translation due to the robust sensitivity, specificity, and reproducibility of these versatile methods. In this review, we provide background information on the fundamental principles of biomarkers and the need for improved treatment strategies in ovarian cancer. We also provide insight into the ways in which mass spectrometry-based targeted proteomics approaches can provide greatly needed solutions to many of the challenges related to ovarian cancer biomarker development.
卵巢癌是女性中最致命的妇科恶性肿瘤。约 70-80%的晚期卵巢癌患者在五年内复发，并产生铂耐药性。铂耐药或铂难治性疾病患者的预期寿命短，这突显了开发新的、更有效的治疗策略的必要性。早期发现是减轻疾病从早期进展为晚期的风险的关键步骤，而蛋白质生物标志物在这一过程中起着不可或缺的作用。卵巢癌最好的生物诊断工具可能是生物标志物的组合。靶向蛋白质组学方法，包括基于质谱的方法，已经成为强大的方法，可以解决最初的生物标志物发现与这些生物标志物的成功验证和确证之间的差距，从而使这些方法具有强大的灵敏度、特异性和重现性，使其能够进行临床转化。在这篇综述中，我们提供了有关生物标志物基本原理和改善卵巢癌治疗策略的必要性的背景信息。我们还深入探讨了基于质谱的靶向蛋白质组学方法如何为与卵巢癌生物标志物开发相关的许多挑战提供急需的解决方案。
